Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, with amyloid plaques accumulation as the key feature involved in its pathology. To date, however, the biochemical changes in AD have not been clearly characterized. Here, we present that urinary metabolomics based on high resolution mass spectrometry was employed for delineation of metabolic alterations in transgenic CRND8 mice. In this noninvasive approach, urinary metabolome reveals the biochemical changes in early onset of this AD mouse model. In virtue of comprehensive metabolite profiling and multivariate statistical analysis, a total of 73 differential metabolites of urine sample sets was identified in 12-week and 18-week transgenic mice compared to wild-type littermates, covering perturbations of aromatic amino acid metabolism, the Krebs cycle and one-carbon metabolism. Of particular interest is that divergent tryptophan metabolism, such as upregulation of serotonin pathway while downregulation of kynurenine pathway, was observed. Meanwhile, the accumulation of both N-acetylvanilalanine and 3-methoxytyrosine indicated aromatic L-amino acid decarboxylase deficiency. And the microbial metabolites derived from aromatic amino acid metabolism and drug-like phase II metabolic response via the glycine conjugation reactions were also highlighted, indicating that genetic modification in mouse brain not only alters genotype but also perturbs the gut microbiome. Together, our study demonstrated that the integrative approach employing mass spectrometry-based metabolomics and a transgenic mouse model for AD may provide new evidence for distinct metabolic signatures. The perturbations of metabolic pathways may have far-reaching implications for early diagnosis and intervention in AD.
Keywords: Alzheimer’s disease, mass spectrometry, metabolomics, noninvasive analysis, transgenic CRND8, tryptophan metabolism, urine.
Current Alzheimer Research
Title:Urinary Metabolomics Reveals Alterations of Aromatic Amino Acid Metabolism of Alzheimer’s Disease in the Transgenic CRND8 Mice
Volume: 13 Issue: 7
Author(s): Zhi Tang, Liangfeng Liu, Yongle Li, Jiyang Dong, Min Li, Jiandong Huang, Shuhai Lin and Zongwei Cai
Affiliation:
Keywords: Alzheimer’s disease, mass spectrometry, metabolomics, noninvasive analysis, transgenic CRND8, tryptophan metabolism, urine.
Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, with amyloid plaques accumulation as the key feature involved in its pathology. To date, however, the biochemical changes in AD have not been clearly characterized. Here, we present that urinary metabolomics based on high resolution mass spectrometry was employed for delineation of metabolic alterations in transgenic CRND8 mice. In this noninvasive approach, urinary metabolome reveals the biochemical changes in early onset of this AD mouse model. In virtue of comprehensive metabolite profiling and multivariate statistical analysis, a total of 73 differential metabolites of urine sample sets was identified in 12-week and 18-week transgenic mice compared to wild-type littermates, covering perturbations of aromatic amino acid metabolism, the Krebs cycle and one-carbon metabolism. Of particular interest is that divergent tryptophan metabolism, such as upregulation of serotonin pathway while downregulation of kynurenine pathway, was observed. Meanwhile, the accumulation of both N-acetylvanilalanine and 3-methoxytyrosine indicated aromatic L-amino acid decarboxylase deficiency. And the microbial metabolites derived from aromatic amino acid metabolism and drug-like phase II metabolic response via the glycine conjugation reactions were also highlighted, indicating that genetic modification in mouse brain not only alters genotype but also perturbs the gut microbiome. Together, our study demonstrated that the integrative approach employing mass spectrometry-based metabolomics and a transgenic mouse model for AD may provide new evidence for distinct metabolic signatures. The perturbations of metabolic pathways may have far-reaching implications for early diagnosis and intervention in AD.
Export Options
About this article
Cite this article as:
Tang Zhi, Liu Liangfeng, Li Yongle, Dong Jiyang, Li Min, Huang Jiandong, Lin Shuhai and Cai Zongwei, Urinary Metabolomics Reveals Alterations of Aromatic Amino Acid Metabolism of Alzheimer’s Disease in the Transgenic CRND8 Mice, Current Alzheimer Research 2016; 13 (7) . https://dx.doi.org/10.2174/1567205013666160129095340
DOI https://dx.doi.org/10.2174/1567205013666160129095340 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Opiate Addiction Therapies and HIV-1 Tat: Interactive Effects on Glial [Ca<sup>2+</sup>]<sub>i</sub>, Oxyradical and Neuroinflammatory Chemokine Production and Correlative Neurotoxicity
Current HIV Research From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Default Mode, Executive Function, and Language Functional Connectivity Networks are Compromised in Mild Alzheimer´s Disease
Current Alzheimer Research The Modulation of Beneficial and/or Harmful Effects of Free Oxygen Radicals in the Context of Molecular Mechanisms Regarding Drug – PART I
Current Topics in Medicinal Chemistry Anticancer Agents: VTA or VDA
Current Bioactive Compounds Protective Effects of Polydatin Against Dementia-Related Disorders
Current Neuropharmacology New Therapeutic Strategy for Parkinson’s and Alzheimer’s Disease
Current Medicinal Chemistry The Anterior-posterior Functional Connectivity Disconnection in the Elderly with Subjective Memory Impairment and Amnestic Mild Cognitive Impairment
Current Alzheimer Research Drug Abuse, Brain Calcification and Glutamate-Induced Neurodegeneration
Current Drug Abuse Reviews A Comparison Between Quetiapine and Aripiprazole for Treatment of Schizophrenia: A Double Blind Contrast
Current Psychopharmacology The Regulation of Brain Nucleoside Utilization
Current Metabolomics Targeting Post-Translational Remodeling of Ryanodine Receptor: A New Track for Alzheimer's Disease Therapy?
Current Alzheimer Research Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions
Current Alzheimer Research The Immune System and the Brain: Crosstalk with a Broad Impact From Host Defense to Cognition
Current Neurovascular Research MicroRNA Landscape in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Editorial (New Wave from Immunology, Endocrine & Metabolic Agents in Medicinal Chemistr )
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Bromelain Degrades Aβ1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimer’s Disease Patients
Current Alzheimer Research